City Therapeutics' Upsized $200M IPO Joins Biotech Wave
Blood clot-focused biotechnology firm City Therapeutics began trading publicly Friday after raising $200 million in its upsized initial public offering steered by Goodwin Procter LLP and Cooley LLP, joining a recent...To view the full article, register now.
Already a subscriber? Click here to view full article